Experimental cancer pill targets Hard-to-Treat gene mutations

NCT ID NCT06270082

Terminated Disease control Sponsor: Ikena Oncology Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early study tested an experimental oral drug called IK-595 in people with advanced solid tumors that have specific RAS or RAF gene mutations. The goal was to check safety, dosing, and early signs of tumor shrinkage. The study was terminated before completion, so full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IK-595 (oral tablet)
What this could lead to: If successful, this could point toward a new treatment option for patients with certain gene-altered advanced solid tumors.
What could go wrong: This was a very early (Phase 1) study that was terminated, so results are limited. The drug may not prove safe or effective in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm glioma malignant glioma malignant pancreatic neoplasm melanoma neoplasm non-small cell lung carcinoma pancreatic neoplasm thyroid gland carcinoma Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAF GENE MUTATION COLORECTAL CANCER CRAF GENE MUTATION GLIOMAS, MALIGNANT MALIGNANT MELANOMA NON-SMALL CELL LUNG CARCINOMA PANCREATIC CANCER RAS (KRAS OR NRAS) GENE MUTATION SOLID TUMOR, ADULT THYROID CARCINOMA

Contacts and locations

Locations

City of Hope

Duarte, California, 91010, United States
INOVA Schar Cancer Institute

Fairfax, Virginia, 22031, United States
Johns Hopkins University of Medicine Sidney Kimmel Comprehensive Care Center

Washington D.C., District of Columbia, 20016, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Next Oncology

Austin, Texas, 78758, United States
Next Oncology- San Antonio

San Antonio, Texas, 78229, United States
START Midwest

Grand Rapids, Michigan, 49546, United States
Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States
Sarah Cannon Research Institute at HealthOne

Denver, Colorado, 80218, United States
Thomas Jefferson University

Philadelphia, Pennsylvania, 19107, United States
University of California Irvine

Orange, California, 92868, United States
University of Chicago

Chicago, Illinois, 60637, United States
University of Miami

Miami, Florida, 33136, United States
University of Pittsburgh Medical Center- Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.